What it is claimed to help
These are the uses attached to IGF-1 LR3 in research, clinical practice, or marketing. Listing a claim is not endorsing it — tap any of them to see every other compound carrying the same claim.
What the human evidence actually is
Cell culture, theory, or research-reagent status. Not tested in animals for this use, let alone people.
None. IGF-1 LR3 was engineered to resist binding proteins so it stays active in laboratory cell culture. It was never developed as a human therapeutic and has no human trials of any kind. Native IGF-1 (mecasermin) is approved for severe IGF-1 deficiency and carries hypoglycaemia warnings — that is the closest relevant human safety signal.
How it is supposed to work
IGF-1 receptor agonist with reduced IGFBP binding, so systemic activity is unnaturally prolonged.
Safety
Serious hypoglycaemia risk by analogy with mecasermin. Chronic IGF-1 receptor stimulation raises theoretical concerns about tumour promotion. No human safety data exists.
Storage and handling
Lyophilised peptide is generally stored at 2–8 °C, or below −20 °C for long-term storage. Reconstituted in bacteriostatic water (0.9% benzyl alcohol) a solution is typically treated as usable for about 28 days refrigerated, versus roughly 24 hours for plain sterile water, which has no preservative. Add the water slowly down the vial wall and swirl — never shake, which shears peptide chains and foams the solution.
Whatever number a protocol or a prescriber gave you, converting it into syringe units is where a misplaced decimal becomes a tenfold error. Our calculators do that conversion and nothing else — they never invent a dose.
Open the calculatorsSources
- FDA prescribing information, Increlex (mecasermin) — for comparison
- Manufacturer research-reagent documentation
- WADA Prohibited List
Verified against primary sources on 27 August 2026. Regulatory status in this field changes several times a year. See How We Rate Evidence.